We believe we're not in the business of medication;
we're in the heart of it

50 Years of Business Experience.

SSPL Unit I

US FDA inspected API manufacturing site

SSPL Unit II

GMP site for manufacturing Steroids and Hormones

Finished Dosage Human

Established division with licensing opportunities

Finished Dosage Veterinary

Animal health care
division

With multiple API and intermediate manufacturing sites in India and its forays into selling its own finished formulations, SSPL is fully integrated for its key products, making it an excellent partner of choice for companies looking at highest levels of quality, compliance and price.

From molecules to milestones

Rooted Dedication

We aim to deliver two to three new product opportunities in global markets in the next 5 years.

Taking science to market

More Efficient

Better costs

Repurposing old molecules with new indications

SSPL’s ultimate goal is to bring new health solutions for suffering patients and deliver the same to them with compassion and empathy

0 +

Years Of Experience

0 +

Presence in countries

0 +

APIs commercialized

0 +

Manufacturing capacity

Industry Testimonials

I am really glad that your company has taken up the commercial production of the drug Pentosan Polysulphate Sodium. This is indeed very commendable achievement of which you can certainly be proud of. All of us in the industry are happy for you and hope that you can expand your manufacture in the complex area of carbohydrate chemistry.

Dr. Y.K. Hamied Chairman, Cipla

Dear Vishal, I extend my congratulations to you and the entire team for the recent successful US FDA inspection. With the foundation that was laid by Late Mr. Narayan Jajodia, our relationship goes back over a few decades. The high degree of commitment which you have shown to grow your father’s business is really commendable. It is impressive that under your leadership, the company has developed expertise in complex molecules and polysaccharide chemistry. I believe that the development of Pentosan Polysulfate Sodium (PPS) for interstitial cystitis is a very important milestone for the company. I hope you will continue the work with dedication and will achieve many such milestones ahead.

Mr. Dilip Shanghvi Managing Director, Sun Pharmaceutical Industries Ltd.

Mr. Vishal deserves to be appreciated for his creative, innovative and industrious attitude and approach. His vision and dream to play globally has come true with launching of the generic molecule Pentosan Polysulphate Sodium globally.

Mr. Binish Chudgar Managing Director, Intas Pharmaceutical

Mr. Narayan Jajodia was very supportive and the first imports by us in 1988 were indented by him. Subsequently he encouraged in expanding the product range and supplied key APIs at reasonable terms and arranging meeting with suppliers at various pharma trade fairs internationally. The legacy of Mr. Narayan Jajodia as a visionary has been aptly executed by his sons Mr. Vishal and Vivek. Both are committed individuals with whom transactions have an unmistakable stamp of quality. Pentosan Polysulphate Sodium has an interesting role in urology and nephrology. More clinical trials need to be undertaken to expand its clinical indications. It is a complex molecule which Mr. Vishal has been keen to develop through his dedication and an able team. His passion to develop niche molecules and commitment of resources to such chemistry is the true legacy of Mr. Narayan Jajodia.

Dr. Rajendra Agarwal Managing Director, Macleods Pharmaceuticals Ltd.

Your efforts to establish a product which has a complicated chemistry successfully has made all of us extremely proud. We can never forget the co-operation and initial support given by your group when we ventured into this effort of creating Elder Pharma. The enthusiasm and honesty with which you work will certainly take your company forward.

Mr. Jagdish Saxena Late Chairman, Elder Pharmaceuticals

SSPL has for the first time in the world, launched a generic drug where the treatment cost of the brand product was USD 25000 and only available in the US for over 20 years. We have made the generic available in India and in several countries at approximately 1200 USD (5% of the originator). SSPL also holds patents on diseases related to kidney where presently there are no medicines available to suffering patients.

SSPL has for the first time in the world, launched a generic drug where the treatment cost of the brand product was USD 25000 and only available in the US for over 20 years. We have made the generic available in India and in several countries at approximately 1200 USD (5% of the originator). SSPL also holds patents on diseases related to kidney where presently there are no medicines available to suffering patients.

Certificates